The FDA has approved Rejoyn, a prescription digital therapeutic app developed by Otsuka Pharmaceutical and Click Therapeutics, specifically designed to help patients with major depressive disorder. Designed as a six-week program to be used in conjunction with traditional antidepressants, Rejoyn employs clinically validated cognitive emotional training aimed at targeting specific areas of the brain affected by depression to gradually reduce symptoms.
Following this breakthrough, Otsuka announced the formation of a new subsidiary, Otsuka Precision Health (OPH), which falls under the umbrella of Otsuka America. This new company is dedicated to the commercialization of Rejoyn as well as the development and marketing of other upcoming digital and connected health products. OPH's strategy is to ensure that treatments like Rejoyn are not only effective but also accessible and affordable, which are often noted challenges in the digital therapeutics industry.
The app, set to be available this summer, will require users to undergo a virtual consultation and receive a prescription. After obtaining an access code from a pharmacy, patients can activate the program directly in the app. OPH President Sanket Shah stated that the company is focused on enhancing patient experience services in the U.S. market and is committed to leveraging technology to understand and improve the patient care journey.
Click here to read the original news story.